[go: up one dir, main page]

PE20230255A1 - Anticuerpo anti-ox40 y usos del mismo - Google Patents

Anticuerpo anti-ox40 y usos del mismo

Info

Publication number
PE20230255A1
PE20230255A1 PE2022002227A PE2022002227A PE20230255A1 PE 20230255 A1 PE20230255 A1 PE 20230255A1 PE 2022002227 A PE2022002227 A PE 2022002227A PE 2022002227 A PE2022002227 A PE 2022002227A PE 20230255 A1 PE20230255 A1 PE 20230255A1
Authority
PE
Peru
Prior art keywords
antibody
antigen
treating
preparation
conditions
Prior art date
Application number
PE2022002227A
Other languages
English (en)
Inventor
Yizhen Yang
Yu Cai
Xiong Li
Lei Zhou
Weiguo Qing
Wei-Guo Su
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PE20230255A1 publication Critical patent/PE20230255A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invencion provee un anticuerpo anti-OX40 o un fragmento que se une al antigeno del mismo, un metodo de preparacion para el mismo y el uso para tratar enfermedades o condiciones relacionadas con OX40.
PE2022002227A 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo PE20230255A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010304381 2020-04-17
PCT/CN2021/087616 WO2021209019A1 (en) 2020-04-17 2021-04-16 Anti-ox40 antibody and uses thereof

Publications (1)

Publication Number Publication Date
PE20230255A1 true PE20230255A1 (es) 2023-02-07

Family

ID=78084656

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022002227A PE20230255A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo
PE2022002226A PE20230682A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2022002226A PE20230682A1 (es) 2020-04-17 2021-04-16 Anticuerpo anti-ox40 y usos del mismo

Country Status (16)

Country Link
US (3) US20230242657A1 (es)
EP (2) EP4136117A4 (es)
JP (2) JP2023523395A (es)
KR (2) KR20230015328A (es)
CN (2) CN115461367A (es)
AR (2) AR121857A1 (es)
AU (2) AU2021256799A1 (es)
BR (2) BR112022020742A2 (es)
CA (2) CA3175407A1 (es)
CL (2) CL2022002830A1 (es)
IL (2) IL297294A (es)
MX (2) MX2022012915A (es)
PE (2) PE20230255A1 (es)
PH (2) PH12022552741A1 (es)
TW (2) TWI877350B (es)
WO (2) WO2021209020A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023523395A (ja) * 2020-04-17 2023-06-05 ハチソン メディファルマ リミテッド 抗ｏｘ４０抗体及びその使用
WO2025021131A1 (en) * 2023-07-25 2025-01-30 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Methods of treating alopecia areata and atopic dermatitis
WO2025161898A1 (en) * 2024-02-02 2025-08-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ox40 antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5426300A (en) 1993-09-17 1995-06-20 Leybold Inficon, Inc. Portable GCMS system using getter pump
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2242771B1 (en) 2007-12-14 2013-07-17 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
SMT201900242T1 (it) * 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
PE20161571A1 (es) 2014-03-31 2017-02-07 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CN115109158A (zh) * 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
JP2018521019A (ja) * 2015-06-08 2018-08-02 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体を使用して癌を治療する方法
JP6771551B2 (ja) * 2015-10-15 2020-10-21 ディンフー バイオターゲット カンパニー リミテッド 抗ｏｘ４０抗体及びその応用
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
SG10201914126RA (en) * 2016-12-15 2020-02-27 Abbvie Biotherapeutics Inc Anti-ox40 antibodies and their uses
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
JP2021501801A (ja) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
CN112292397B (zh) 2017-11-24 2023-01-31 祐和医药科技(北京)有限公司 抗ox40抗体及其用途
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
EA202092460A1 (ru) * 2018-05-23 2021-03-24 Бейджин, Лтд. Антитела к ox40 и способы применения
CN110003338B (zh) * 2019-04-16 2021-04-23 北京免疫方舟医药科技有限公司 抗ox40抗体及其应用
CN110004177A (zh) * 2019-04-22 2019-07-12 中国食品药品检定研究院 一种检测抗ox40抗体的方法及其应用
JP2023523395A (ja) * 2020-04-17 2023-06-05 ハチソン メディファルマ リミテッド 抗ｏｘ４０抗体及びその使用

Also Published As

Publication number Publication date
JP2023521475A (ja) 2023-05-24
US20230151105A1 (en) 2023-05-18
AR121858A1 (es) 2022-07-20
CL2022002830A1 (es) 2023-06-09
EP4136116A1 (en) 2023-02-22
TW202144424A (zh) 2021-12-01
WO2021209019A1 (en) 2021-10-21
AU2021256226A1 (en) 2022-11-17
MX2022012915A (es) 2022-11-16
CA3175413A1 (en) 2021-10-21
CN115461367A (zh) 2022-12-09
WO2021209020A1 (en) 2021-10-21
IL297292A (en) 2022-12-01
JP2023523395A (ja) 2023-06-05
AR121857A1 (es) 2022-07-20
IL297294A (en) 2022-12-01
TWI873332B (zh) 2025-02-21
CN115461366B (zh) 2025-11-11
AU2021256799A1 (en) 2022-11-17
US12030951B2 (en) 2024-07-09
BR112022020741A2 (pt) 2022-12-20
PE20230682A1 (es) 2023-04-21
MX2022012913A (es) 2022-11-14
US20240301077A1 (en) 2024-09-12
EP4136117A4 (en) 2024-04-10
CN115461366A (zh) 2022-12-09
CA3175407A1 (en) 2021-10-21
EP4136117A1 (en) 2023-02-22
CL2022002829A1 (es) 2023-06-09
EP4136116A4 (en) 2024-06-19
KR20230015327A (ko) 2023-01-31
PH12022552725A1 (en) 2023-01-04
PH12022552741A1 (en) 2024-02-12
KR20230015328A (ko) 2023-01-31
TW202144423A (zh) 2021-12-01
BR112022020742A2 (pt) 2022-12-20
JP7760525B2 (ja) 2025-10-27
TWI877350B (zh) 2025-03-21
US20230242657A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
CL2022002829A1 (es) Anticuerpo anti-ox40 y usos del mismo
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
MX2018012473A (es) Agentes que reconocen el epitopo de clever-1 y usos de los mismos.
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2021000146A1 (es) Anticuerpos humanizados contra psma
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
BR112023023453A8 (pt) Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste, composições farmacêuticas e usos do referido anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste
CL2024003486A1 (es) Anticuerpo anti-b7h3 y usos del mismo
CO2024007361A2 (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
BR112022021641A2 (pt) Tratamento de combinação de anticorpos anti-cd40 para câncer
MX2019013804A (es) Combinacion de un anticuerpo biespecifico de erbb-2/erbb-3 con terapia endocrina para cancer de mama.
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
MX2020003034A (es) Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
EA201892244A1 (ru) МОНОВАЛЕНТНЫЙ ИНГИБИТОР ВЗАИМОДЕЙСТВИЯ huTNFR1
PE20230765A1 (es) Anticuerpo anti-cd47 y usos del mismo
MX2021002647A (es) Metodos de tratamiento de la psoriasis.
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
CL2021001021A1 (es) Anticuerpo anti-cldn18.2 y sus usos.
AR122715A1 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina